Danvatirsen

Synonyms: AZD9150
Danvatirsen (AZD9150) 是一种靶向 STAT3 的反义寡核苷酸,可降低白血病细胞系活力并促进其凋亡 (Apoptosis),抑制内源性 STAT3 及其下游靶基因的表达,降低神经母细胞瘤、淋巴瘤细胞增殖能力与成瘤性,在神经母细胞瘤、淋巴瘤、非小细胞肺癌小鼠模型中抑制肿瘤生长,在表皮样癌小鼠模型中实现 STAT3 mRNA 及蛋白耗竭,可用于淋巴瘤、骨髓增生异常综合征、急性髓系白血病、神经母细胞瘤及非小细胞肺癌的相关研究。
产品编号: MS-E65100 纯度: 99.12% CAS No.: 1402357-06-5 分子量: 5422.00
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Danvatirsen (AZD9150) 是一种靶向 STAT3 的反义寡核苷酸,可降低白血病细胞系活力并促进其凋亡 (Apoptosis),抑制内源性 STAT3 及其下游靶基因的表达,降低神经母细胞瘤、淋巴瘤细胞增殖能力与成瘤性,在神经母细胞瘤、淋巴瘤、非小细胞肺癌小鼠模型中抑制肿瘤生长,在表皮样癌小鼠模型中实现 STAT3 mRNA 及蛋白耗竭,可用于淋巴瘤、骨髓增生异常综合征、急性髓系白血病、神经母细胞瘤及非小细胞肺癌的相关研究。

生物实验数据

生物活性 Danvatirsen (AZD9150) is an antisense oligonucleotide targeting STAT3 that reduces the viability of leukemia cell lines and promotes their apoptosis (Apoptosis), inhibits the expression of endogenous STAT3 and its downstream target genes, decreases the proliferative capacity and tumorigenicity of neuroblastoma and lymphoma cells, suppresses tumor growth in mouse models of neuroblastoma, lymphoma, and non-small cell lung cancer, achieves STAT3 mRNA and protein depletion in a mouse model of epidermoid carcinoma, and can be used for research related to lymphoma, myelodysplastic syndromes, acute myeloid leukemia, neuroblastoma, and non-small cell lung cancer.
体外研究
(In Vitro)

Danvatirsen (2.5-10 μM) 可显著降低 KG1a、CMK、MOLM13 和 KT1 白血病细胞系中的 STAT3 mRNA 水平。
Danvatirsen (1-10 μM; 24-72 h) 可显著降低 NB4、MOLM14、MDS-L、MV411、KG1a、MOLM13、KT1 和 CMK 白血病/骨髓增生异常综合征 (MDS) 细胞系的活力。
Danvatirsen (5 μM (CMK), 10 μM (KT1, U937); 48 h) 可显著提高 CMK、KT1 和 U937 白血病细胞系的细胞凋亡水平。
Danvatirsen (2.5-10 μM; 24 h) 可显著降低原发性 MDS/AML 干细胞中的 STAT3 mRNA 水平。
Danvatirsen (10 μM; 14 days) 可增强原发性骨髓增生异常综合征 (MDS) 干/祖细胞的红系和髓系分化。
Danvatirsen (10 μM; 24 h) 可在 CMK 白血病细胞中在 mRNA 水平下调 STAT3 及其下游致癌靶基因 (IL1RAP、MSI2、MCL1、IL8、CXCR2),下调 CMK 白血病细胞中 STAT3、磷酸化 STAT3 以及 MCL1 的蛋白水平。
Danvatirsen 可在原代 TP53 突变型 MDS/AML 干/祖细胞中诱导剂量依赖性凋亡,降低集落实验中原代 AML 干细胞和祖细胞的再接种效率。
Danvatirsen (0.25-10 μM; 6 days) 可剂量依赖性地抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中 STAT3 mRNA 的表达,IC50 值分别为 0.69、0.64 和 0.76 μM。
Danvatirsen (0.25-10 μM; 6 days) 可剂量依赖性地抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中总 STAT3 蛋白及磷酸化 STAT3 蛋白的表达,IC50 值分别为 0.99 μM、0.97 μM 和 0.98 μM。
Danvatirsen (1 μM; 6 days) 可显著降低 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞中多个 STAT3 靶基因的 mRNA 和蛋白表达水平。
Danvatirsen (1 μM; 4 weeks) 可显著抑制 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞的增殖,在持续孵育过程中分别使细胞汇合度降低最高达 38%、37% 和 34%,抑制细胞的锚定非依赖性集落形成,使集落数量分别减少 20%、43% 和 67%。
Danvatirsen (1 μM; 6 days) 可显著增强 SK-N-AS、NGP 和 IMR32 神经母细胞瘤细胞对 Cisplatin (MS-E94993) 的敏感性,使Cisplatin 的 IC50 值降低最多 2 倍,并可减弱 Cisplatin 诱导的 DNA 损伤应答通路激活。
Danvatirsen (0.005-5 μM; 5 days) 可通过自由摄取方式剂量依赖性地抑制 STAT3 依赖性人淋巴瘤细胞系 KARPAS299 和 SUP-M2 的增殖。

Cell Viability Assay

Cell Line: NB4, MOLM14, MDS-L, MV411, KG1a, MOLM13, KT1, CMK leukemic/MDS cell lines
Concentration: 10 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Induced a significant, dose-dependent decrease in cell viability across all tested cell lines.
Showed greater inhibition at higher concentrations.

Apoptosis Analysis

Cell Line: CMK, KT1, U937 leukemic cell lines
Concentration: 5 μM (CMK cells); 10 μM (KT1 and U937 cells)
Incubation Time: 48 h
Result: Induced a significant increase in early apoptotic, late apoptotic, and necrotic cell populations compared with controls.
Showed a dose-dependent effect observed across tested concentrations.

Real Time qPCR

Cell Line: CMK leukemic cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Downregulated expression of STAT3 and oncogenic/stem cell-associated genes including IL1RAP, MSI2, MCL1, IL8, and CXCR2 at the mRNA level.

Western Blot Analysis

Cell Line: CMK leukemic cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Reduced STAT3 protein, phospho-STAT3, and MCL1 protein levels.

Real Time qPCR

Cell Line: SK-N-AS, NGP, IMR32 human neuroblastoma cell lines
Concentration: 0.25-10 μM
Incubation Time: 6 days
Result: Inhibited STAT3 mRNA levels in a dose-dependent manner.
Achieved IC50 values of 0.69 μM in SK-N-AS cells, 0.64 μM in NGP cells, and 0.76 μM in IMR32 cells.

Western Blot Analysis

Cell Line: SK-N-AS, NGP, IMR32 human neuroblastoma cell lines
Concentration: 0.25-10 μM
Incubation Time: 6 days
Result: Decreased both total and phosphorylated STAT3 (Ser727, Tyr705) protein levels in a dose-dependent manner.
Achieved IC50 values of 0.99 μM in SK-N-AS cells, 0.97 μM in NGP cells, and 0.98 μM in IMR32 cells.

Cell Proliferation Assay

Cell Line: SK-N-AS, NGP, IMR32 human neuroblastoma cell lines
Concentration: 1 μM
Incubation Time: continuous incubation (up to 240 hours)
Result: Caused a significant decrease in cell growth: up to 38% decrease in SK-N-AS cells, up to 37% decrease in NGP cells, and up to 34% decrease in IMR32 cells.

Cell Viability Assay

Cell Line: SK-N-AS, NGP, IMR32 human neuroblastoma cell lines
Concentration: 1 μM
Incubation Time: 3 days pre-incubation, followed by 3 days co-incubation with cisplatin
Result: Significantly increased cisplatin sensitivity, resulting in a 2-fold decrease in cisplatin IC50 in NGP cells and IMR32 cells, and a smaller decrease in SK-N-AS cells.
Attenuated cisplatin-induced activation of the ATM and ATR DNA damage response pathways, as shown by reduced phosphorylation of ATM, Chk2, ATR, Chk1, and γH2AX.

Cell Proliferation Assay

Cell Line: KARPAS299, SUP-M2 (human lymphoma cell lines)
Concentration: 0.005-5 μM
Incubation Time: 5 days
Result: Induced dose-dependent inhibition of cell proliferation in KARPAS299 and SUP-M2 cells.
Showed antiproliferative effects that correlated with the degree of STAT3 depletion.
体内研究
(In Vivo)

Danvatirsen (50 mg/kg,s.c.,每周 5 天,持续 4 周) 可显著降低人 MDS/AML 细胞在 NSG 小鼠中的植入率。
Danvatirsen (100 mg/kg;s.c.;每周 5 次;持续 3 周) 联合 Cisplatin 可使神经母细胞瘤异种移植物的生长抑制率最高达 38%,并显著延长荷瘤小鼠的生存期。
Danvatirsen (25-50 mg/kg;s.c.;每周 5 次;持续 3 周) 可在人表皮样癌 A431 异种移植瘤中实现强效、剂量依赖性的 STAT3 mRNA 及蛋白耗竭,其中 25 mg/kg 剂量可使肿瘤 STAT3 mRNA 水平降低 90%。
Danvatirsen (50 mg/kg,s.c.,每周 5 次,持续 5 周) 可抑制人淋巴瘤 SUP-M2 异种移植物的生长,抑制率达 62%,并使肿瘤 STAT3 mRNA 水平降低约 40%,在播散性 SUP-M2 模型中表现出全身性抗淋巴瘤活性,可使肿瘤 STAT3 mRNA 降低约 50%,并降低血浆 sIL-2Rα 和 sCD30 的浓度。
Danvatirsen (25 mg/kg;s.c.;每周 5 次;约 5 周) 可将 PC-9 人非小细胞肺癌异种移植物的生长抑制 90%,并降低 STAT3 活性及下游靶基因的表达。

Animal Model: Nonobese Diabetic Scid Gamma (NSG) (irradiated, engrafted with primary human MDS/AML peripheral blood mononuclear cells)
Dosage: 50 mg/kg
Administration: s.c.; 5 days per week; 4 weeks
Result: Reduced MDS/AML burden, with greatly decreased fold change of human CD45+ cells in bone marrow compared with controls.
Achieved complete loss of detectable human CD45+ cells in some treated mice.
Exerted effects in both low-risk and high-risk MDS patient-derived xenografts.
Animal Model: athymic nude mice (5-6 week-old female)
Dosage: 100 mg/kg (target reagent); 2 mg/kg (Cisplatin)
Administration: subcutaneous (target reagent; 5 times per week; 3 weeks); intraperitoneal (cisplatin; 2 times per week; 3 weeks; co-administered starting on day 11 of target reagent treatment)
Result: Reduced neuroblastoma xenograft growth by up to 38% compared to control-treated mice.
Prolonged survival significantly compared to control-treated mice.
Animal Model: Immunocompromised mice; NSG mice (disseminated lymphoma model)
Dosage: 25 mg/kg; 37.5 mg/kg; 50 mg/kg
Administration: 5 times per week; 3 weeks (25 mg/kg, 50 mg/kg)
Result: Reduced tumor STAT3 mRNA by approximately 90% (P=0.0001) and STAT3 protein by 93% (25 mg/kg).
Produced near-complete depletion of STAT3 protein throughout the tumor as measured by immunohistochemistry (50 mg/kg).
Animal Model: NSG mice, Immunocompromised mice
Dosage: 50 mg/kg
Administration: 5 times per week; 2, 5 weeks
Result: Reduced STAT3 mRNA by ~50% in tumors isolated from axillary lymph nodes and peritoneal cavity vs control groups.
Reduced plasma sIL-2Rα and sCD30 concentrations.
Reduced tumor burden (and ascites formation.
Achieved 67% tumor growth inhibition (TGI).
Confirmed inhibition of human STAT3 in tumor cells and murine STAT3 in tumor-associated stromal cells via species-specific PCR.
Confirmed reduced phospho-STAT3 protein in both human tumor and mouse stromal cells via immunohistochemistry.
No associated change in body weight was observed.
Animal Model: Immunocompromised mice
Dosage: 25 mg/kg
Administration: 5 times per week; ~5 weeks
Result: Achieved 90% tumor growth inhibition (TGI) vs control.
Reduced tumor STAT3 and phospho-STAT3 protein, and reduced expression of STAT3 target genes c-MYC, MCL-1, and VEGF.
性状 固体
颜色 White to off-white

化学信息

分子量 5422.00
CAS No. 1402357-06-5
别名 AZD9150

储存&溶解度

储存方式

-20°C, stored under nitrogen

*In solvent: -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 100 mg/mL (18.44 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM0.1844 mL0.9222 mL1.8443 mL4.6108 mL
5 mM0.0369 mL0.1844 mL0.3689 mL0.9222 mL
10 mM0.0184 mL0.0922 mL0.1844 mL0.4611 mL
15 mM0.0123 mL0.0615 mL0.1230 mL0.3074 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (stored under nitrogen)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础